Palsy

Cerebral Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cerebral...

$2,000.00

Cerebral Palsy Disease - Global Clinical Trials Review, H2, 2020

Tue, 15 Dec 2020 12:29:33 +0000

Summary

GlobalData's clinical trial report, “Cerebral Palsy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cerebral Palsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Cerebral Palsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competiti...

$2,500.00

Progressive Supranuclear Palsy - Pipeline Review, H2 2016

Fri, 07 Apr 2017 13:51:23 +0000

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Progressive Supranuclear Palsy Overview 7
Therapeutics Development 8
Pipeline Products for Progressive Supranuclear Palsy - Overview 8
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 9
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 10
Progressive Supranuclear Palsy - Therapeutics under Investigation by Universities/Institutes 11
Progressive Supranuclear Palsy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Progressive Supranuclear Palsy - Products under Development by Companies 15
Progressive Supranuclear Palsy - Products under Investigation by Universities/Institutes 16
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 17
AB Science SA 17
AbbVie Inc 18
AlzProtect SAS 19
Asceneuron SA 20
Bristol-Myers Squibb Company 21
Cortice Bioscienc...

$2,000.00

Epiomic Epidemiology Series: Bell's Palsy Forecast in 15 Major Markets 2017-2027

Thu, 09 Mar 2017 15:20:59 +0000

Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell’s palsy is characterised by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell’s palsy. This report provides the current incident population for Bell’s palsy across 15 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Bell’s palsy have been quant...

$6,400.00

Cerebral Palsy - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Cerebral Palsy - Pipeline Review, H2 2016’, provides an overview of the Cerebral Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor present...

$2,000.00

Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2016" provides an overview of Spastic Cerebral Palsy clinical trials scenario. This report provides top line data relating to the clinical trials on Spastic Cerebral Palsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategie...

$2,500.00

Cerebral Palsy - Pipeline Review, H1 2016

Sat, 28 May 2016 19:12:44 +0000

Summary

Global Markets Direct’s, ‘Cerebral Palsy - Pipeline Review, H1 2016’, provides an overview of the Cerebral Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor present...

$2,000.00